Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. (Form: 8-K, Received: 01/09/2017 10:59:53)

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549


 

FORM 8-K


CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 9 , 201 7


 

Aviragen Therapeutics , Inc.

(Exact name of registrant as specified in its charter)


 

Delaware

001-35285

59-1212264

(State or other jurisdiction

of incorporation)

(Commission  

File Number)

(IRS Employer

Identification No.)

 

 

 

2500 Northwinds Parkway, Suite 100

Alpharetta, GA

30009

 

(Address of principal executive offices)

(Zip Code)

 

Registrant ’s telephone number, including area code: ( 678 ) 221 - 3350

 

Not Applicable

(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

 

 

Item 7 .01 Regulation FD Disclosure

 

Aviragen Therapeutics, Inc. is furnishing the investor presentation attached as Exhibit 99.1 to this report, which it may use from time to time in conversations with investors, analysts, and others beginning January 9, 2017.  

 

The information in this report is being furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for purposes of Section 17 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference with any filing under the Securities Act of 1933, as amended, or the Exchange Act.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits

99.1

 

Investor Presentation, dated January 2017

   
   

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Aviragen Therapeutics , Inc.

   

Date: January 9, 2017

/s/ Joseph M Patti

 

Name:

Joseph M Patti

 

Title:

Chief Executive Officer and President

   

(Duly Authorized Officer)

 


 

EXHIBIT INDEX

Exhibit

Number

 

Description

99.1

 

Investor Presentation, dated January 2017

 

 

Exhibit 99.1